Hepatitis C

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

By

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

Recipients of Popular Facial May Have Been Exposed to HIV, Hepatitis

Recipients of Popular Facial May Have Been Exposed to HIV, Hepatitis

Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.

Sign Up for Free e-newsletters